Samsung Bioepis gets EC's approval for Opuviz

South Korea's Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, and the US-based Biogen said on Tuesday the European C...

Samsung Bioepis Q1 sales surpass $362 mn in US, Europe

Samsung Bioepis Co. reported that its quarterly overseas sales of key biosimilars exceeded 500 billion won ($362 million), according to figures re...

Samsung Bioepis seeks to buy Biogen biosimilar unit

Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea’s Samsung Group, seeks to buy a biosimilar business d...

Samsung buys $2.3 bn Bioepis stake from Biogen to end partnership

Samsung Biologics Co. is acquiring a nearly 50% stake in a biosimilar joint venture with Biogen Inc. from the US biotechnology company for $2.3 bill...

Samsung Group in negotiations to buy Biogen

South Korea's Samsung Group is in negotiations to buy Biogen Inc., a leading US-based drugmaker for neurological conditions such as Alzheimer's and ...